Notably, all tested cell lines carrying BRAF fusions were resistant to vemurafenib and dabrafenib, sharply distinguishing them from BRAFV600E mutant cell lines…although they harbored the exact same AGK-BRAF fusion. Globally, the C022 cell line showed a higher level of resistance to the tested drugs than C0902 (Figure 4a).